Table 3.
Univariate and multivariate analyses of RFS and OS prognostic factors in HCC patients (n=175).
| RFS | OS | |||
|---|---|---|---|---|
| Clinicopathologic variable | HR (95% CI) | P | HR (95% CI) | P |
| Univariate analysis† | ||||
| Gender (male vs. female) | 1.061 (0.867-1.584) | 0.215 | 1.106 (0.923-1.316) | 0.135 |
| Age, years (> 60 vs. ≤ 60) | 1.215 (0.986-1.764) | 0.085 | 1.161 (0.952-1.417) | 0.141 |
| HBsAg (positive vs. negative) | 1.298 (0.981-1.992) | 0.064 | 1.135 (0.869-1.538) | 0.061 |
| Albumin, g/L (≤35 vs. >35) | 1.052 (0.897-1.963) | 0.089 | 1.195 (0.995-1.436) | 0.056 |
| Child-Pugh classification (B vs. A) | 1.231 (1.053-1.768) | 0.037 | 1.292 (1.084-1.852) | 0.043 |
| Liver cirrhosis (presence vs. absence) | 1.312 (1.097-1.635) | 0.016 | 1.369 (1.106-3.145) | 0.013 |
| Serum AFP level, ng/mL (> 20 vs. ≤ 20) | 1.452 (1.079-1.894) | 0.036 | 1.209 (1.012-2.174) | 0.046 |
| Tumor diameter, cm (> 5 vs. ≤ 5) | 1.554 (1.116-3.425) | 0.012 | 1.405 (1.106-2.642) | 0.021 |
| Tumor number (multiple vs. single) | 1.659 (1.107-2.827) | 0.008 | 1.554 (1.106-2.993) | 0.014 |
| Tumor encapsulation (none vs. complete) | 1.152 (0.932-1.436) | 0.072 | 1.304 (1.046-2.214) | 0.025 |
| Vascular invasion (presence vs. absence) | 2.113 (1.462-4.834) | <0.0001 | 2.056 (1.279-6.164) | <0.0001 |
| Tumor differentiation (III/IV vs. I/II) | 1.478 (1.187-1.769) | 0.022 | 1.352 (0.994-1.967) | 0.069 |
| Satellite nodules (presence vs. absence) | 1.841 (1.267-3.156) | 0.004 | 1.731 (1.036-1.948) | 0.010 |
| TH (presence vs. absence) | 1.947 (1.296-6.324) | 0.003 | 1.874 (1.236-3.524) | 0.007 |
| TNM stage (II/III vs. I) | 1.212 (1.067-1.836) | 0.040 | 1.546 (1.142-2.284) | 0.018 |
| BOLA2 expression level (high vs. low) | 2.024 (1.186-3.895) | 0.002 | 1.942 (1.246-4.537) | 0.005 |
| Multivariate analysis† | ||||
| Gender (male vs. female) | NA | NA | ||
| Age, years (> 60 vs. ≤ 60) | NA | NA | ||
| HBsAg (positive vs. negative) | NA | NA | ||
| Albumin, g/L (≤35 vs. >35) | NA | NA | ||
| Child-Pugh classification (B vs. A) | 1.078 (0.967-1.842) | NS | 1.208 (0.997-1.463) | NS |
| Liver cirrhosis (presence vs. absence) | 1.102 (0.954-1.863) | NS | 1.398 (0.981-1.992) | NS |
| Serum AFP level, ng/mL (> 20 vs. ≤ 20) | 1.135 (0.869-1.538) | NS | 1.364 (0.967-1.842) | NS |
| Tumor diameter, cm (> 5 vs. ≤ 5) | 1.195 (0.995-1.436) | NS | 1.154 (0.859-1.729) | NS |
| Tumor number (multiple vs. single) | 1.874 (1.236-3.524) | 0.007 | 1.768 (1.023-3.969) | 0.019 |
| Tumor encapsulation (none vs. complete) | NA | 1.075 (0.951-1.375) | NS | |
| Venous invasion (presence vs. absence) | 2.152 (1.336-5.231) | <0.0001 | 1.994 (1.253-4.564) | 0.002 |
| Tumor differentiation (III/IV vs. I/II) | 1.208 (0.946-1.764) | NS | NA | |
| Satellite nodules (presence vs. absence) | 1.679 (1.214-3.216) | 0.021 | 1.616 (1.207-3.542) | 0.024 |
| TH (presence vs. absence) | 2.342 (1.678-7.429) | <0.0001 | 1.856 (1.246-5.682) | 0.005 |
| TNM stage (II/III vs. I) | 1.229 (1.016-1.488) | 0.035 | 1.231 (1.084-1.796) | 0.041 |
| BOLA2 expression level (high vs. low) | 2.108 (1.541-6.067) | 0.004 | 2.253 (1.341-6.568) | <0.001 |
Abbreviations: HCC, hepatocellular carcinoma; RFS, recurrence-free survival; OS, overall survival; HR, hazard ratio; CI, confidential interval; NA, not adopted; HBsAg, hepatitis B surface antigen; AFP, α-fetoprotein; TH, tumor hemorrhage; TNM, tumor-node-metastasis, unless otherwise indicated. A significant difference is shown in bold.
† Cox proportional hazards regression.